Bioethics Commission Releases Final Neuroscience Report as Part of BRAIN Initiative
By Misti Ault Anderson,
The blog of the Presidential Commission for the Study of Bioethical Issues
| 03. 26. 2015
Untitled Document
The Presidential Commission for the Study of Bioethical Issues today released Gray Matters: Topics at the Intersection of Neuroscience, Ethics, and Society(Gray Matters, Vol. 2), the second of its two volume report in response to President Obama’s BRAIN Initiative related charge. The President requested that the Bioethics Commission consider the ethical issues associated with neuroscience research and the application and implications of neuroscience research findings. Gray Matters, Vol. 2takes an in-depth look at three controversial topics at the intersection of neuroscience and society that have captured the public’s attention—cognitive enhancement, consent capacity, and neuroscience within the legal system. In the first volume, Gray Matters: Integrative Approaches for Neuroscience, Ethics, and Society, released in May 2014, the Bioethics Commission emphasized the importance of integrating ethics and neuroscience early and explicitly throughout the research endeavor. Programs that integrate neuroscience and ethics will be well-positioned to answer new and remaining ethical questions, consider societal implications of neuroscience research, educate the public, and implement policy recommendations. The three topics addressed in Gray Matters, Vol. 2 illustrate the ethical...
Related Articles
By Keith Casebonne and Jodi Beckstine [with CGS' Katie Hasson], Disability Deep Dive | 07.24.2025
In this episode of Disability Deep Dive, hosts Keith and Jodi explore the complex interplay between disability science, technology, and ethics with guest Katie Hasson, Associate Director at the Center for Genetics and Society. The conversation delves into...
By Angus Liu, Fierce Pharma | 07.22.2025
A brief skirmish between Sarepta Therapeutics and the FDA has ended before escalating into a full-on regulatory clash, as the company has bowed to the agency’s demand.
In a surprising reversal, Sarepta on Monday said it will pause all shipments...
By Lucy Tu, The Atlantic | 07.11.2025
Donald Trump—who is, by his own accounting, “the fertilization president” and “the father of IVF”—wants to help Americans reproduce. During his 2024 campaign, he promised that the government or insurance companies would cover the cost of in vitro fertilization. In...
By Jared Whitlock, Endpoints News | 07.15.2025
Patient groups face a harder and unpredictable path going state-by-state to boost screening for rare but treatable conditions after the Trump administration disbanded a federal advisory committee on newborn screening.
In April, the Advisory Committee on Heritable Disorders in Newborns...